treatment-free survival

• 

Outcomes of patients who stopped immunotherapy due to immune-related side effects

By Sharon Deveson Kell|2022-02-09T14:47:05+00:009 Feb 2022|Drug treatments|

Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]

Read More

Comments Off on Outcomes of patients who stopped immunotherapy due to immune-related side effects

• 

ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer

By Sharon Kell|2020-09-18T09:15:47+00:0018 Sep 2020|Uncategorized|

Over the past 2 years, the use of combination therapies [...]

Read More

Comments Off on ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer

• 

Rational approaches to treatment duration with immunotherapy for kidney cancer

By Sharon Kell|2020-01-17T17:17:41+00:0017 Jan 2020|Drug treatments|

A recent review of the use of immune checkpoint inhibitors [...]

Read More

Comments Off on Rational approaches to treatment duration with immunotherapy for kidney cancer

• 

Extended duration of active surveillance of small renal masses

By Sharon Kell|2019-07-26T11:16:06+00:0026 Jul 2019|Cancer news|

A recent study published in the Journal of Urology evaluated [...]

Read More

Comments Off on Extended duration of active surveillance of small renal masses

• 

ESMO 2018: Longer treatment-free survival for ipilimumab/nivolumab combination versus sunitinib

By Sharon Kell|2018-10-23T15:27:37+00:0023 Oct 2018|Drug treatments|

Analysis of the phase 3 CheckMate-214 study has shown that [...]

Read More

Comments Off on ESMO 2018: Longer treatment-free survival for ipilimumab/nivolumab combination versus sunitinib